- Home
- ARMP vs PEPG Comparison
ARMP vs PEPG Comparison
Compare ARMP & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- PEPG
- Stock Information
- Founded
- ARMP N/A
- PEPG 2018
- Country
- ARMP United States
- PEPG United States
- Employees
- ARMP N/A
- PEPG N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- PEPG Health Care
- Exchange
- ARMP Nasdaq
- PEPG Nasdaq
- Market Cap
- ARMP 80.0M
- PEPG 64.2M
- IPO Year
- ARMP N/A
- PEPG 2022
- Fundamental
- Price
- ARMP $2.11
- PEPG $1.37
- Analyst Decision
- ARMP Strong Buy
- PEPG Buy
- Analyst Count
- ARMP 1
- PEPG 3
- Target Price
- ARMP $7.00
- PEPG $14.67
- AVG Volume (30 Days)
- ARMP 8.2K
- PEPG 486.5K
- Earning Date
- ARMP 03-20-2025
- PEPG 03-05-2025
- Dividend Yield
- ARMP N/A
- PEPG N/A
- EPS Growth
- ARMP N/A
- PEPG N/A
- EPS
- ARMP N/A
- PEPG N/A
- Revenue
- ARMP $5,467,000.00
- PEPG N/A
- Revenue This Year
- ARMP $23.87
- PEPG N/A
- Revenue Next Year
- ARMP N/A
- PEPG N/A
- P/E Ratio
- ARMP N/A
- PEPG N/A
- Revenue Growth
- ARMP 34.92
- PEPG N/A
- 52 Week Low
- ARMP $1.80
- PEPG $1.16
- 52 Week High
- ARMP $4.48
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- ARMP 56.44
- PEPG 31.82
- Support Level
- ARMP $1.85
- PEPG $1.16
- Resistance Level
- ARMP $2.08
- PEPG $1.60
- Average True Range (ATR)
- ARMP 0.12
- PEPG 0.14
- MACD
- ARMP 0.00
- PEPG 0.11
- Stochastic Oscillator
- ARMP 56.67
- PEPG 48.28
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.